

Overview**Useful For**

Confirmatory detection of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2)-specific IgG antibodies in spinal fluid specimens that are consistently reactive by initial screening tests

Differentiating between HTLV-1- and HTLV-2-specific IgG antibodies present in spinal fluid

Method Name

Line Immunoassay (LIA)

NY State Available

Yes

Specimen**Specimen Type**

CSF

Advisory Information

This confirmatory assay should be ordered only on specimens that are consistently reactive by an antihuman T-cell lymphotropic virus 1 and 2 (HTLV-1/-2) screening immunoassay.

For an evaluation that includes both screening and confirmation, order HTLVC / Human T-Cell Lymphotropic Virus Types 1 and 2 (HTLV-1/-2) Antibody Screen with Confirmation, Spinal Fluid.

Specimen Required

Collection Container/Tube: Sterile vial

Specimen Volume: 0.5 mL

Specimen Minimum Volume

0.2 mL

Reject Due To

Gross hemolysis	Reject
Gross lipemia	Reject
Gross icterus	OK

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
CSF	Frozen (preferred)	30 days	
	Refrigerated	14 days	

Clinical and Interpretive

Clinical Information

Human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) are closely related exogenous human retroviruses. HTLV-1 was first isolated in 1980 from a patient with a cutaneous T-cell lymphoma, while HTLV-2 was identified from a patient with hairy cell leukemia in 1982.

HTLV-1 infection is endemic in southwestern Japan, Caribbean basin, Melanesia, and parts of Africa, where HTLV-1 seroprevalence rates are as high as 15% in the general population. In the United States, the combined HTLV-1 and HTLV-2 seroprevalence rate is about 0.016% among voluntary blood donors. About half of these infected blood donors are infected with HTLV-1, with most of them reporting a history of birth in HTLV-1-endemic countries or sexual contact with persons from the Caribbean or Japan. Smaller percentages report a history of either injection drug use or blood transfusion. Transmission of HTLV-1 occurs from mother to fetus, sexual contact, blood transfusion, and sharing of contaminated needles. Two diseases are known to be caused by HTLV-1 infection: adult T-cell leukemia or lymphoma (ATL) and a chronic degenerative neurologic disease known as HTLV-1-associated myelopathy (HAM) or tropical spastic paraparesis (TSP). Cases of polymyositis, chronic arthropathy, panbronchiolitis, and uveitis have also been reported in HTLV-1-infected patients.

HTLV-2 is prevalent among injection drug users in the United States and in Europe, and more than 80% of HTLV infections in drug users in the United States are due to HTLV-2. HTLV-2 also appears to be endemic in Native American populations, including the Guaymi Indians in Panama and Native Americans in Florida and New Mexico. HTLV-2-infected blood donors most often report either a history of injection drug use or a history of sexual contact with an injection drug user. A smaller percentage of infected individuals report a history of blood transfusion. HTLV-2 is transmitted similarly to HTLV-1, but much less is known about the specific modes and efficiency of transmission of HTLV-2. The virus can be transmitted by transfusion of cellular blood products (whole blood, red blood cells, and platelets). HTLV-2 infection has been associated with hairy-cell leukemia, but definitive evidence is lacking on a viral etiologic role. HTLV-2 has also been linked with neurodegenerative disorders characterized by spastic paraparesis and variable degrees of ataxia.

Infection by these viruses results in the appearance of specific antibodies against the viruses that can be detected by serologic tests such as enzyme immunoassay. For accurate diagnosis of HTLV-1 or HTLV-2 infection, all initial screening test-reactive results should be verified by a confirmatory test, such as Western blot or line immunoassay.

Reference Values

Negative

Interpretation

Negative confirmatory test results indicate the absence of both human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2)-specific IgG antibodies in spinal fluid and a low probability of an HTLV-1/-2-associated neurologic disorder.

A reactive screening result with a negative or indeterminate confirmatory (line immunoassay) test result suggests either a false-reactive screening test result or a seroconverting HTLV infection. Repeat testing in 1 to 2 months can clarify the final infection status. Persistently indeterminate confirmatory test results indicate an absence of HTLV infection.

Positive results for HTLV-1 antibodies indicate the confirmed presence of HTLV-1 IgG antibodies in spinal fluid, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the sum of the gp46-I and p19-I band intensity is greater than the gp46-II band intensity.

Positive results for HTLV-2 antibodies indicate the confirmed presence of HTLV-2 IgG antibodies in spinal fluid, based on 2 visible antibody bands that include gp21-I/-II band, or 3 or more bands, and the gp46-II band intensity is a) greater than the gp46-I band intensity and b) equal or greater than the sum of the gp46-I and p19-I band intensity.

Indeterminate results indicate the presence of the gp21-I/-II band only or combination of any 2 bands without a detectable gp21-I/-II band. Patients with indeterminate test results with known risk factors for HTLV-1 or HTLV-2 infection should undergo repeat confirmatory antibody testing in 1 to 2 months to determine final infection status.

Differentiation of HTLV-1 and HTLV-2 infection is not possible (ie, nontypeable HTLV antibodies) when the band intensity pattern does not meet the criteria of positive HTLV-1 or HTLV-2 antibody band intensity pattern.

Unreadable results indicate the presence of nonspecific background reactivity that is inhibiting the visualization of specific bands on the test strip. Repeat testing in 1 to 2 months is recommended.

Invalid results indicate that nonspecific band reactivity is present. Submit another specimen for retesting, if clinically indicated.

Cautions

A negative line immunoassay result does not preclude the possibility of exposure to human T-cell lymphotropic virus types 1 and 2.

Results from this confirmatory assay should always be interpreted together with the reactive screening test result on a given specimen.

Clinical Reference

1. Mahieux R, Gessain A: Adult T-cell leukemia/lymphoma and HTLV-I. *Curr Hematol Malig Rep* 2007;2(4):257-264
2. DeCastro-Costa CM, Araujo AQ, Barreto MM, et al: Proposal for diagnostic criteria of tropical spastic paraparesis / HTLV-I-associated myelopathy (TSP / HAM). *AIDS Res Hum Retroviruses* 2006;22:931-935
3. Yamano Y, Sato T: Clinical pathophysiology of human T-lymphotropic virus-type I-associated myelopathy/tropical spastic paraparesis. *Front Microbiol* 2012 3:1-10
4. Gessain A, Mahieux R: Tropical spastic paraparesis and HTLV-I associated myelopathy: clinical, epidemiological, virological, and therapeutic aspects. *Rev Neurol (Paris)* 2012;168(3):257-269

Performance

Method Description

INNO-LIA HTLV I/II Score is a line immunoassay based on the enzyme immunoassay (EIA) principle. The assay uses well-defined antigens derived from human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) immunodominant proteins. The antigens used are either recombinant proteins or synthetic peptides, highly purified and fixed on a nylon membrane strip. The sequences are selected to allow the detection of antibodies with a wide specificity to all known isolates of the HTLV strains. The antigenicity exhibited by these proteins and peptides is either common to both HTLV-1 and HTLV-2, or type-specific to 1 of the 2 viruses to allow confirmation and discrimination in a single assay. Two *gag* (p19-I/II, p24-I/II) and 2 *env* (gp46-I/II, gp21-I/II) bands are applied as nontype-specific antigens, which are used to confirm the presence of antibodies against HTLV-1/2. The type-specific antigens for HTLV-1 (*gag* p19-I, *env* gp46-I) and for HTLV-2 (*env* gp46-II) are applied to differentiate between HTLV-1 and HTLV-2 infections. In addition, 4 control lines are coated: 1 negative control (streptavidin), and 3 positive control lines: a strong (antihuman IgG), a moderate (human IgG), and a weak (human IgG) line.

A test sample is incubated in a test trough together with the multiple antigen-coated strip. Specific anti-HTLV antibodies, if present in the sample, will bind to the HTLV antigen lines on the strip. Subsequently, goat-antihuman IgG labeled with alkaline phosphatase is added and will bind to any HTLV antigen-antibody complex previously formed. Incubation with a chromogenic substrate produces a dark brown color in proportion to the amount of specific antibodies present in the sample. The color development is stopped with sulfuric acid. If the sample contains no HTLV-specific antibodies, only a low background color develops. (Package insert: INNO-LIA HTLV I/II Score, 25221 v3, Fujirebio Europe NV, 12/2017)

PDF Report

No

Day(s) and Time(s) Test Performed

Wednesday; 12 p.m.

Analytic Time

2 days

Maximum Laboratory Time

15 days

Specimen Retention Time

14 days

Performing Laboratory Location

Rochester

Fees and Codes
Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

86689

LOINC® Information

Test ID	Test Order Name	Order LOINC Value
HTLLC	HTLV -1/-2 Ab Confirmation, CSF	93744-1

Result ID	Test Result Name	Result LOINC Value
604935	HTLV-1/-2 Ab Confirmation, CSF	93745-8
604945	HTLV-1/-2 Bands	93743-3

Result ID	Test Result Name	Result LOINC Value
604946	HTLV-1/-2 Discrimination	93742-5